Iqtopam (Clonazepam): Uses, Dosage & Side Effects
A benzodiazepine anticonvulsant solution for injection used in the treatment of epilepsy and status epilepticus in adults and adolescents aged 12 years and older
Iqtopam (clonazepam 1 mg/ml solution for injection) is a benzodiazepine anticonvulsant used to treat various forms of epilepsy, including status epilepticus, in adults and adolescents aged 12 years and older. Clonazepam works by enhancing the activity of gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter, which reduces neuronal excitability and suppresses seizure activity. Iqtopam is administered as a slow intravenous injection, intravenous infusion, or intramuscular injection in hospital settings under close medical supervision. It is a prescription-only medication and, as a benzodiazepine, is classified as a controlled substance in many countries. This guide provides comprehensive, evidence-based information about Iqtopam including its uses, dosage, side effects, drug interactions, and important safety considerations.
Quick Facts: Iqtopam
Key Takeaways
- Iqtopam (clonazepam 1 mg/ml) is a benzodiazepine injection used to treat various forms of epilepsy, including status epilepticus, in adults and adolescents aged 12 years and older. It provides rapid seizure control when administered intravenously.
- The medication must be administered slowly with continuous monitoring of EEG, respiration, and blood pressure, and should only be given in a hospital or clinical setting by trained healthcare professionals.
- Iqtopam must not be used in patients with severe breathing difficulties, severe liver problems, a history of substance abuse, or in children under 12 years of age. Comatose patients must not receive this medication.
- Like all benzodiazepines, Iqtopam carries a risk of physical dependence and withdrawal symptoms. Treatment must never be stopped abruptly, as this can provoke severe seizures, including tonic-clonic convulsions and status epilepticus.
- Alcohol must be completely avoided during treatment. Combining Iqtopam with opioids or other central nervous system depressants significantly increases the risk of profound sedation, respiratory depression, and potentially fatal outcomes.
What Is Iqtopam and What Is It Used For?
Iqtopam contains the active substance clonazepam, which belongs to the benzodiazepine class of medications. Benzodiazepines are among the most widely used drugs in clinical medicine, and clonazepam specifically has well-established anticonvulsant, anxiolytic (anxiety-reducing), and muscle relaxant properties. As an injectable formulation, Iqtopam is designed for situations where rapid drug delivery is necessary, such as in the emergency management of acute seizures or status epilepticus, and for patients who cannot take oral medication.
Clonazepam exerts its pharmacological effects by binding to the benzodiazepine binding site on the GABA-A receptor, the most important inhibitory receptor complex in the central nervous system. The GABA-A receptor is a ligand-gated chloride ion channel. When GABA (gamma-aminobutyric acid) binds to this receptor, chloride ions flow into the neuron, causing hyperpolarization of the cell membrane and reducing the likelihood of the neuron firing an action potential. Clonazepam enhances this natural process by increasing the frequency of chloride channel opening in the presence of GABA. This allosteric modulation results in increased inhibitory neurotransmission throughout the brain, which effectively suppresses the abnormal, excessive electrical activity that characterizes epileptic seizures.
The onset of action following intravenous administration is rapid, typically within 1 to 3 minutes, making it particularly valuable in the acute management of seizure emergencies. After reaching the brain, clonazepam distributes widely throughout the central nervous system. It is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4, to its major metabolite 7-aminoclonazepam and other inactive compounds. The elimination half-life is relatively long, ranging from 30 to 40 hours in adults, which contributes to its sustained anticonvulsant effect but also means that effects can persist for a considerable time after administration.
Iqtopam is approved for use in the following clinical situations:
- Status epilepticus: A medical emergency defined as a continuous seizure lasting more than 5 minutes or two or more seizures occurring within 5 minutes without the person returning to normal between them. Status epilepticus requires immediate treatment to prevent brain damage, and intravenous benzodiazepines like clonazepam are a cornerstone of acute management. International guidelines from the International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES) recommend benzodiazepines as first-line treatment for convulsive status epilepticus.
- Various forms of epilepsy: Iqtopam can be used for the treatment of different epilepsy types in adults and adolescents aged 12 years and older. Clonazepam has broad-spectrum anticonvulsant activity and is effective against multiple seizure types, including generalized tonic-clonic seizures, absence seizures, myoclonic seizures, and certain focal seizure types. It may be used as a short-term adjunctive therapy or when oral treatment is not feasible.
While clonazepam is highly effective in the acute management of seizures, its long-term use as a maintenance anticonvulsant is generally limited by the development of tolerance. Many patients develop tolerance to the anticonvulsant effects of benzodiazepines after weeks to months of continuous use, meaning the drug becomes less effective at controlling seizures over time. For this reason, injectable clonazepam formulations like Iqtopam are primarily reserved for acute and emergency situations rather than long-term seizure management. When long-term treatment is needed, clonazepam is typically used as an adjunct to other antiepileptic drugs rather than as monotherapy.
Status epilepticus is a neurological emergency that requires immediate medical intervention. Without prompt treatment, prolonged seizure activity can lead to irreversible brain injury, systemic complications including hyperthermia, metabolic acidosis, and rhabdomyolysis, and in severe cases, death. The rapid onset of action of intravenous clonazepam makes Iqtopam a valuable tool in the emergency physician’s and neurologist’s arsenal for achieving rapid seizure control in these critical situations.
What Should You Know Before Receiving Iqtopam?
Before receiving Iqtopam, it is essential that your healthcare team is fully informed about your medical history, current medications, and any allergies. Benzodiazepines like clonazepam have a wide range of pharmacological effects beyond seizure suppression, and certain medical conditions or drug combinations can increase the risk of serious adverse effects. The following sections detail the contraindications, warnings, and precautions that must be considered before and during treatment.
Contraindications
Iqtopam must not be used in the following situations. These are absolute contraindications, meaning the medication should never be administered under these circumstances:
- Hypersensitivity: Do not receive Iqtopam if you are allergic to clonazepam, any other benzodiazepine (such as diazepam or nitrazepam), or any of the excipients listed in the product information (anhydrous ethanol, benzyl alcohol, concentrated acetic acid, propylene glycol).
- Severe respiratory insufficiency: Iqtopam must not be used in patients with severe breathing difficulties because benzodiazepines cause respiratory depression, which can worsen pre-existing respiratory compromise to a life-threatening degree.
- Severe hepatic impairment: Patients with severe liver disease must not receive Iqtopam because clonazepam is extensively metabolized by the liver. Severe hepatic impairment can lead to dangerous accumulation of the drug and its metabolites, greatly increasing the risk of excessive sedation and respiratory depression.
- History of substance abuse: Iqtopam should not be given to patients with a current or past history of alcohol, drug, or medication abuse, due to the significant risk of benzodiazepine dependence and misuse.
- Children under 12 years of age: Iqtopam is not approved for use in children under 12 years. The safety and efficacy of this specific formulation have not been established in this age group.
- Comatose patients: Iqtopam must not be administered to patients in a coma because benzodiazepines can further depress consciousness and respiratory function.
Warnings and Precautions
The concurrent use of benzodiazepines such as clonazepam with opioid medications (including strong painkillers, opioid substitution therapies, and certain cough medicines) carries a serious risk of profound sedation, respiratory depression, coma, and death. This combination should only be used when no alternative treatment options are available, and even then, the lowest effective doses should be used for the shortest possible duration under close monitoring.
Tell your doctor or nurse before receiving Iqtopam if any of the following apply to you:
- Depression or suicidal thoughts: If you have ever been depressed or have attempted suicide, inform your healthcare provider. Benzodiazepines can exacerbate depression, and antiepileptic drugs as a class have been associated with a small increased risk of suicidal ideation. Close monitoring is essential.
- Mild to moderate liver problems: While severe liver disease is a contraindication, even mild to moderate hepatic impairment can affect clonazepam metabolism. Your doctor may need to adjust the dose and monitor liver function during treatment.
- Lung disease: If you have a pulmonary condition that affects your breathing, such as chronic obstructive pulmonary disease (COPD) or sleep apnea, the respiratory depressant effects of clonazepam may pose an increased risk. The dose will be carefully adjusted to your respiratory status.
- Myasthenia gravis: If you have this rare neuromuscular disease characterized by severe muscle weakness, clonazepam can worsen muscle weakness and should be used with extreme caution.
- Elderly patients: Older adults are more sensitive to the effects of benzodiazepines, including sedation, confusion, impaired coordination, and increased fall risk. Lower doses are typically recommended, and monitoring should be more frequent.
- Porphyria: If you have the rare inherited blood disorder porphyria, inform your doctor, as benzodiazepines may trigger acute attacks in susceptible individuals.
- Paradoxical reactions: In some patients, benzodiazepines can cause unexpected reactions opposite to the intended effects, including restlessness, agitation, irritability, aggression, anxiety, delusions, anger, nightmares, hallucinations, psychosis, and other behavioral disturbances. These paradoxical reactions are more common in children and the elderly. If such reactions occur, treatment should be gradually discontinued.
- Anterograde amnesia: Benzodiazepines, including clonazepam, can cause anterograde amnesia (inability to form new memories) even at therapeutic doses. The risk increases with higher doses. This amnesia may sometimes be associated with inappropriate behavior.
Dependence and Withdrawal
Physical and psychological dependence can develop with benzodiazepine use, even at therapeutic doses and with relatively short treatment durations. The risk of dependence increases with dose and duration of treatment, and is particularly high in patients with a history of substance abuse. If dependence develops, abrupt discontinuation may lead to severe withdrawal symptoms including seizures.
Like all benzodiazepines, clonazepam carries a risk of physical and psychological dependence. This is particularly relevant for patients who receive repeated doses or prolonged treatment. Withdrawal symptoms can occur if the drug is stopped suddenly after regular use. These symptoms include tremors, restlessness, sleep disturbances, anxiety, headache, difficulty concentrating, sweating, muscle and abdominal pain, confusion, and in rare cases, delirium and convulsions. Treatment with Iqtopam should only be discontinued under medical supervision, with gradual dose reduction to minimize the risk of withdrawal reactions.
Pregnancy and Breastfeeding
Iqtopam should be used during pregnancy only if the potential benefit to the mother clearly justifies the risk to the unborn child. Clonazepam crosses the placenta, and its active ingredients can reach the fetus. While no definitive human teratogenicity data exist, animal studies and clinical experience with benzodiazepines as a class suggest potential risks including neonatal sedation, hypotonia (reduced muscle tone), feeding difficulties, and respiratory depression, particularly if the drug is administered near the time of delivery. Additionally, regular use during pregnancy can lead to neonatal withdrawal symptoms in the newborn.
Clonazepam passes into breast milk, and there is a risk that the nursing infant may be affected by the drug. Therefore, breastfeeding must be discontinued during treatment with Iqtopam. Women of childbearing age should discuss effective contraception with their healthcare provider prior to treatment.
Driving and Operating Machinery
Iqtopam significantly impairs the ability to drive vehicles, operate machinery, or perform any activities requiring alertness and quick reaction times. This effect is a direct consequence of the drug’s central nervous system depressant properties. You must not drive or engage in potentially dangerous activities after receiving Iqtopam, especially during the first few days of treatment, until you know how the medication affects you. The sedative effects may persist for many hours due to the long elimination half-life of clonazepam. Any consumption of alcohol while receiving this medication will dramatically increase impairment.
Important Information About Excipients
Iqtopam contains several excipients that require special attention:
- Benzyl alcohol (31 mg per ampoule): Benzyl alcohol may cause allergic reactions in susceptible individuals. If you are pregnant or breastfeeding, you should consult your doctor before receiving this medication. Large amounts of benzyl alcohol can accumulate in the body and cause metabolic acidosis.
- Ethanol (158 mg per ampoule): Each ampoule contains a small amount of alcohol equivalent to approximately 4 ml of beer or 2 ml of wine. This amount is unlikely to produce noticeable effects in adults and adolescents. However, the alcohol content may affect the action of other medications. If you have or have had alcohol dependence, inform your healthcare provider. If the medication is given slowly over 2 hours, the effects of the alcohol content can be minimized.
- Propylene glycol (805 mg per ampoule): This excipient requires caution in patients who are pregnant, breastfeeding, or who have impaired liver or kidney function. Your doctor may wish to perform additional monitoring during treatment.
How Does Iqtopam Interact with Other Drugs?
Drug interactions with Iqtopam are clinically significant because clonazepam acts on the central nervous system and is metabolized by the liver enzyme CYP3A4. Medications that also depress the CNS can have additive or synergistic effects when combined with clonazepam, potentially leading to dangerous levels of sedation, respiratory depression, and even death. Similarly, drugs that induce or inhibit CYP3A4 can alter clonazepam blood levels, affecting both efficacy and safety. It is essential to inform your doctor about all medications you are taking, including prescription drugs, over-the-counter products, and herbal supplements.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Opioids (morphine, fentanyl, codeine, methadone, buprenorphine) | Profound sedation, respiratory depression, coma, death | Avoid combination; use only if absolutely necessary with close monitoring |
| Phenytoin | Phenytoin levels may increase or decrease; clonazepam levels may decrease | Monitor serum levels of both drugs; dose adjustments often needed |
| Phenobarbital | Additive CNS depression; may reduce clonazepam levels through enzyme induction | Dose adjustment required; monitor for excessive sedation |
| Carbamazepine | Decreases clonazepam plasma levels through CYP3A4 induction | Reduced clonazepam efficacy; consider dose increase with monitoring |
| Valproic acid | May increase risk of absence seizures (absence status); potential for increased sedation | Use combination with caution; monitor for absence status epilepticus |
Other Significant Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Lamotrigine | Mutual pharmacokinetic interactions possible; sedation may increase | Monitor for increased side effects; dose adjustments may be needed |
| St. John’s Wort (Hypericum perforatum) | May decrease clonazepam levels through CYP3A4 induction | Avoid combination; reduced anticonvulsant efficacy possible |
| Other CNS depressants (sedatives, antipsychotics, certain antihistamines, anesthetics) | Additive sedation, respiratory depression, and psychomotor impairment | Use lowest effective doses; monitor respiratory function closely |
| CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, grapefruit juice) | May increase clonazepam plasma levels and prolong its effects | Monitor for increased sedation and side effects; dose reduction may be needed |
When Iqtopam is used in combination with other antiepileptic drugs, dosage adjustments are usually necessary to achieve the optimal therapeutic effect while minimizing toxicity. Your neurologist or treating physician will carefully monitor drug levels and clinical response when prescribing combinations of anticonvulsants. The interactions between antiepileptic drugs are complex and bidirectional, meaning that adding or removing one drug from the regimen can affect the levels and efficacy of all other drugs in the combination.
Alcohol
Alcohol consumption is strictly contraindicated during treatment with Iqtopam. Alcohol, like clonazepam, is a CNS depressant, and the combination produces synergistic depression of brain function. Even small amounts of alcohol can dramatically increase sedation and impair judgment, coordination, and reaction times. More dangerously, the combination significantly increases the risk of life-threatening respiratory depression. Patients must be clearly informed that they must not consume any alcoholic beverages while receiving or recovering from treatment with Iqtopam.
What Is the Correct Dosage of Iqtopam?
Iqtopam dosing is individualized and depends on the patient’s age, body weight, clinical condition, and response to treatment. The medication is only administered in a hospital or clinical setting by trained healthcare professionals. The doctor or nurse may dilute Iqtopam with sodium chloride (saline) or glucose solution before administration to ensure you receive the precise dose needed. The medication can be given as a slow intravenous injection, as an intravenous infusion (drip), or as an intramuscular injection if the physician deems it necessary.
Slow Intravenous Injection
Acute Treatment (Status Epilepticus)
Route: Slow intravenous injection
Preparation: The contents of one ampoule (1 mg clonazepam in 1 ml) must be diluted with 1.0 ml of water for injections before administration to prevent local irritation at the injection site
Administration: Inject slowly directly into a vein with continuous monitoring of EEG, respiration, and blood pressure
Note: The injection solution must be prepared immediately before administration. This route is intended for acute treatment, not long-term therapy
Intravenous Infusion
Longer-Term Parenteral Treatment
Route: Intravenous infusion (drip)
Preparation: Diluted in compatible IV fluids (0.9% sodium chloride, 0.45% NaCl + 2.5% glucose, 5% glucose, or 10% glucose)
Administration: Infuse slowly with continuous monitoring of EEG, respiration, and blood pressure
Stability: Diluted solutions are stable for up to 2 hours at room temperature (25°C) and in the refrigerator (2–8°C). From a microbiological standpoint, use immediately after dilution
Important: Do not use PVC-containing bags or infusion sets, as clonazepam is significantly adsorbed by PVC, reducing the active substance concentration by up to 50%. Use non-PVC containers and infusion equipment
Intramuscular Injection
Exceptional Circumstances Only
Route: Intramuscular injection
Use: Only when intravenous access is impossible
Preparation: Do not dilute for IM injection, as dilution makes the injection more painful
Note: Absorption is slower and less predictable after IM injection compared to IV administration, making this route less preferred for acute seizure emergencies
Special Populations
| Population | Recommendation | Rationale |
|---|---|---|
| Adults (12+ years) | Standard dosing; individualized by physician | Dose adjusted based on seizure type, severity, and response |
| Elderly patients | Lower starting doses; slower titration | Increased sensitivity to CNS depressants; altered metabolism; higher fall risk |
| Mild to moderate hepatic impairment | Reduced dose; close monitoring of liver function | Impaired metabolism may lead to drug accumulation |
| Respiratory disease | Reduced dose; respiratory monitoring | Risk of respiratory depression is increased |
| Children under 12 years | Contraindicated | Safety and efficacy not established for this formulation |
Overdose
Because Iqtopam is administered in a hospital setting, overdose is unlikely. However, if an excessive dose is given, symptoms may include drowsiness, loss of coordination, slurred speech, involuntary eye movements (nystagmus), absent reflexes, slowed breathing, low blood pressure, respiratory failure, or loss of consciousness. If an overdose is suspected, the medical team must be informed immediately.
The benzodiazepine receptor antagonist flumazenil may be used as a specific antidote in a monitored hospital setting. However, flumazenil must be used with extreme caution in patients with epilepsy, as antagonizing the benzodiazepine effect may trigger seizures. Supportive care, including respiratory support and cardiovascular monitoring, forms the mainstay of overdose management.
Stopping Treatment
Treatment with Iqtopam must never be stopped abruptly. Sudden discontinuation after regular use carries a serious risk of provoking tonic-clonic seizures, status epilepticus, or severe withdrawal symptoms. These withdrawal symptoms can include tremors, restlessness, sleep disturbances, anxiety, headache, difficulty concentrating, sweating, muscle and abdominal pain, confusion, and in rare cases, delirium and convulsions. When treatment needs to be discontinued, the dose must be reduced gradually under close medical supervision.
What Are the Side Effects of Iqtopam?
Like all medicines, Iqtopam can cause side effects, although not everyone who receives it will experience them. The side effects of clonazepam are primarily related to its central nervous system depressant action, meaning that most common side effects involve sedation, reduced alertness, and impaired coordination. These effects are typically most pronounced at the start of treatment and may decrease over time as the body adjusts to the medication. However, some side effects can be serious and require immediate medical attention.
Contact your doctor immediately if you experience any of the following: severe difficulty breathing, signs of a severe allergic reaction (generalized itching, hives, swelling, wheezing, fainting), signs of heart problems (chest pain, irregular heartbeat, sudden shortness of breath), or signs of blood clotting problems (unusual bruising or bleeding from the skin or mucous membranes).
Common Side Effects
- Impaired concentration and reduced alertness
- Drowsiness and excessive sleepiness
- Slow reactions and delayed responses
- Decreased muscle strength
- Dizziness and light-headedness
- Fatigue, tiredness, and apathy
- Muscle weakness
- Problems with coordination of movements and gait (ataxia)
- Rapid involuntary eye movements (nystagmus)
Rare Side Effects
- Thrombocytopenia (low platelet count causing easy bruising and bleeding)
- Changes in sexual desire (libido disturbances)
- Headache
- Nausea and upper abdominal pain
- Urticaria (hives), itching, skin rash, and temporary hair loss
- Skin pigmentation changes
- Urinary incontinence
- Erectile dysfunction in men
Very Rare Side Effects
- Severe anaphylactic reaction (generalized itching, hives, swelling, wheezing, breathing difficulties, fainting)
Frequency Not Known
- Hypersensitivity reactions
- Emotional disturbances, mood changes, confusion, disorientation, depression
- Paradoxical reactions: restlessness, irritability, aggression, agitation, nervousness, hostility, anxiety, sleep disturbances, delusions, anger, nightmares, hallucinations, hyperactivity, psychosis, inappropriate behavior
- Anterograde amnesia (inability to form new memories), which may be associated with inappropriate behavior
- Physical dependence and withdrawal symptoms
- Double vision (diplopia)
- Speech difficulties (dysarthria)
- Epileptic seizures (upon abrupt discontinuation)
- Heart failure, including cardiac arrest
- Respiratory depression
- Venous inflammation (phlebitis) or thrombosis at injection site
- Increased risk of falls and fractures
Paradoxical reactions deserve special attention. These are reactions opposite to what the drug is intended to produce: instead of calming and sedation, the patient may experience agitation, aggression, rage, hallucinations, or other behavioral disturbances. Paradoxical reactions are a class effect of benzodiazepines and are more common in children, adolescents, and elderly patients. If paradoxical reactions occur during treatment with Iqtopam, the treating physician should consider gradual discontinuation of the drug.
Long-term use of benzodiazepines can lead to physical dependence. Once dependence has developed, abrupt cessation or rapid dose reduction can trigger withdrawal symptoms ranging from mild anxiety and insomnia to severe manifestations such as seizures and delirium. The risk of developing dependence increases with higher doses, longer treatment duration, and a personal or family history of substance abuse. Healthcare providers should use the lowest effective dose for the shortest clinically necessary duration.
How Should Iqtopam Be Stored?
Proper storage of Iqtopam is essential to maintain the drug’s stability, potency, and safety. The medication must be kept out of the sight and reach of children at all times. Like all pharmaceutical products, Iqtopam has a defined shelf life and must not be used after the expiry date printed on the carton and ampoule (the expiry date refers to the last day of the stated month).
The key storage requirements for Iqtopam are as follows:
- Temperature: Store at or below 25°C (77°F). Do not freeze the product under any circumstances, as freezing may alter the physical and chemical properties of the solution.
- Light protection: Keep the ampoules in the outer carton at all times when not in use. Clonazepam is light-sensitive, and exposure to light can degrade the active substance, reducing the medication’s effectiveness and potentially forming harmful degradation products.
- After dilution: Diluted solutions for intravenous infusion have demonstrated stability for up to 2 hours at room temperature (25 ± 2°C) and in the refrigerator (2–8°C) when diluted in compatible solutions (0.9% sodium chloride, 0.45% NaCl + 2.5% glucose, 5% glucose, or 10% glucose). However, from a microbiological standpoint, the product should be used immediately after dilution.
- PVC incompatibility: Do not store diluted solutions in PVC-containing bags. Clonazepam is significantly adsorbed by PVC materials, which can reduce the active substance concentration by up to 50%, especially if bags with prepared solution are stored for 24 hours or more in warm conditions, or if long tubing or slow infusion rates are used. Non-PVC containers and infusion sets should always be used.
- Sodium bicarbonate incompatibility: Do not prepare infusions of Iqtopam with sodium bicarbonate solution, as this is chemically incompatible.
Any color changes in the injection or infusion solutions have no effect on the activity or properties of the medication. The solution is normally colorless to slightly yellow-green. Medications should never be disposed of via wastewater or household waste. Ask your pharmacist how to properly dispose of medications that are no longer needed, as these measures help protect the environment.
What Does Iqtopam Contain?
Understanding the full composition of a medication is important both for identifying potential allergens and for understanding how the drug is formulated. Iqtopam is a sterile concentrate designed for injection or infusion, formulated to deliver clonazepam in a stable, injectable form.
Active Ingredient
The active substance is clonazepam. Each milliliter of Iqtopam (one ampoule) contains 1 mg of clonazepam. Clonazepam (chemical name: 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one) is a 1,4-benzodiazepine derivative with a molecular weight of 315.71 g/mol. It is a potent anticonvulsant with additional anxiolytic, sedative, and muscle relaxant properties.
Excipients (Inactive Ingredients)
| Excipient | Amount per Ampoule | Purpose |
|---|---|---|
| Anhydrous ethanol | 158 mg | Co-solvent to maintain clonazepam in solution |
| Benzyl alcohol | 31 mg | Preservative and co-solvent |
| Concentrated acetic acid | As needed for pH adjustment | pH adjustment and stabilization |
| Propylene glycol | 805 mg | Co-solvent to enhance solubility |
Appearance and Packaging
Iqtopam is a colorless to slightly yellow-green sterile concentrate solution. It is packaged in amber-colored translucent borosilicate glass ampoules to protect the light-sensitive active ingredient. Each carton contains 10 ampoules arranged in two plastic trays. The amber glass provides additional protection against photodegradation, helping to maintain the stability and potency of the clonazepam throughout the product’s shelf life.
Marketing Authorization and Manufacturing
The marketing authorization for Iqtopam is held by XGX Pharma ApS, based in Copenhagen, Denmark. The product is manufactured by Netpharmalab Consulting Services, S.L., located in Alcobendas (Madrid), Spain. These details are important for traceability and for reporting any quality concerns or suspected adverse reactions to the appropriate authorities.
Frequently Asked Questions About Iqtopam
Medical References
- Iqtopam Summary of Product Characteristics (SmPC). XGX Pharma ApS. Last revised November 2024. European Medicines Agency (EMA).
- Trinka E, Cock H, Hesdorffer D, et al. “A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus.” Epilepsia. 2015;56(10):1515-1523. Evidence Level: 1A
- Glauser T, Shinnar S, Gloss D, et al. “Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults – Report of the Guideline Committee of the American Epilepsy Society.” Epilepsy Currents. 2016;16(1):48-61. Evidence Level: 1A
- National Institute for Health and Care Excellence (NICE). “Epilepsies in children, young people and adults.” NICE guideline [NG217]. Updated 2024. Evidence Level: 1A
- World Health Organization (WHO). “WHO Model List of Essential Medicines – 23rd List.” Geneva: WHO; 2023. Clonazepam is listed as an essential anticonvulsant.
- Greenblatt DJ, Miller LG, Shader RI. “Clonazepam pharmacokinetics, brain uptake, and receptor interactions.” The Journal of Clinical Psychiatry. 1987;48(Suppl):16-23. Evidence Level: 2B
- Brodie MJ, Besag F, Ettinger AB, et al. “Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review.” Pharmacological Reviews. 2016;68(3):563-602. Evidence Level: 1A
- Lader M. “Benzodiazepine harm: how can it be reduced?” British Journal of Clinical Pharmacology. 2014;77(2):295-301. Evidence Level: 2A
Medical Editorial Team
This article has been written, reviewed, and approved by the iMedic Medical Editorial Team, consisting of licensed specialist physicians and clinical pharmacologists with expertise in neurology and epilepsy management.
Neurology Specialist
Board-certified neurologist with expertise in epilepsy diagnosis, treatment, and management of status epilepticus
Clinical Pharmacologist
Specialist in drug interactions, pharmacokinetics, benzodiazepine pharmacology, and patient safety
Emergency Medicine Physician
Specialist in acute seizure management, critical care, and emergency neurology protocols
Medical Writer
Medical communications specialist ensuring accuracy, accessibility, and compliance with health literacy standards
Editorial Standards: All iMedic content follows the GRADE evidence framework and is reviewed according to international guidelines from the WHO, EMA, FDA, ILAE, and NICE. Content is updated regularly to reflect the latest evidence. No commercial funding or pharmaceutical industry sponsorship influences our editorial content.